Terminated PHASE4 INTERVENTIONAL 1-arm NCT03921294

HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor

Prospective, Single-arm, Open-label Use of Hemlibra (Emicizumab) to Treat Hemophilic Pseudotumor

Sponsor: Genentech, Inc.

Interventions Emicizumab

Updated 9 times since 2019 Last updated: Mar 19, 2024 Started: May 15, 2019 Primary completion: Mar 16, 2022 Completion: Mar 16, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Global COVID-19 pandemic prevented further study visits or enrollment.

Other terminated trials from Genentech, Inc.

More terminations from Genentech, Inc.

This PHASE4 trial investigates Haemophilic Pseudotumour and is currently terminated or withdrawn. Genentech, Inc. leads this study, which shows 9 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
May 2024 — Jul 2024 [monthly]

Terminated PHASE4
Apr 2024 — May 2024 [monthly]

Terminated PHASE4

Status: Completed → Terminated
Sep 2022 — Apr 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed

▶ Show 4 earlier versions

Sep 2021 — Sep 2022 [monthly]

Recruiting PHASE4
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE4
Jan 2020 — Jan 2021 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
May 2019 — Jan 2020 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Indiana Hemophilia &Thrombosis Center, Inc.

Data source: Indiana Hemophilia &Thrombosis Center, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States